MedPath

Clopidogrel

Generic Name
Clopidogrel
Brand Names
Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
Drug Type
Small Molecule
Chemical Formula
C16H16ClNO2S
CAS Number
113665-84-2
Unique Ingredient Identifier
A74586SNO7
Background

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication

1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者,可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点;

2.用于急性冠状动脉综合征(不稳定心绞痛和非ST段抬高心肌梗死)患者;

3.用于冠状动脉支架置入术后预防支架内血栓形成(与阿司匹林联用)。

Associated Conditions
Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
Associated Therapies
-

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

Phase 4
Completed
Conditions
Peripheral Arterial Disease
Interventions
Drug: Ezetimibe
Drug: Niaspan
Drug: Statin therapy
Behavioral: Standard care
Drug: Aspirin
Drug: Placebo Niaspan
Drug: Placebo Ezetimibe
Drug: Clopidogrel
Procedure: Percutaneous transluminal angioplasty (PTA)
First Posted Date
2008-05-30
Last Posted Date
2020-02-06
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
102
Registration Number
NCT00687076
Locations
🇺🇸

Baylor College of Medicine, Houston, Texas, United States

Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

Phase 2
Completed
Conditions
Myocardial Ischemia
Atherosclerosis
Myocardial Infarction
Interventions
First Posted Date
2008-05-26
Last Posted Date
2017-05-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
120
Registration Number
NCT00684203

Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting

Phase 4
Conditions
Coronary Artery Disease
Interventions
Drug: Placebo
Drug: Clopidogrel
First Posted Date
2008-04-18
Last Posted Date
2014-10-09
Lead Sponsor
Deutsches Herzzentrum Muenchen
Target Recruit Count
4005
Registration Number
NCT00661206
Locations
🇺🇸

University of Florida, Health Science Center - Jacksonville, Jacksonville, Florida, United States

🇦🇱

Spitali Gjerman, Tirana, Albania

🇦🇹

Krankenanstalt Rudolfstiftung, Wien, Austria

and more 37 locations

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety

Not Applicable
Completed
Conditions
Coronary Arteriosclerosis
Acute Coronary Syndrome
Interventions
Drug: clopidogrel
Drug: placebo
First Posted Date
2008-03-28
Last Posted Date
2011-06-16
Lead Sponsor
Accumetrics, Inc.
Target Recruit Count
2800
Registration Number
NCT00645918
Locations
🇺🇸

Rhode Island Hospital, Providence, Rhode Island, United States

🇺🇸

The Miriam Hospital, Providence, Rhode Island, United States

🇺🇸

Black Hills Clinical Research Center, Rapid City, South Dakota, United States

and more 79 locations

The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization

Not Applicable
Completed
Conditions
Coronary Artery Disease
Chest Pain
First Posted Date
2008-03-27
Last Posted Date
2011-10-07
Lead Sponsor
University of Oklahoma
Target Recruit Count
27
Registration Number
NCT00644657
Locations
🇺🇸

VA Medical Center, 1F187, Oklahoma City, Oklahoma, United States

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

Phase 2
Completed
Conditions
Stable Coronary Artery Disease
Interventions
First Posted Date
2008-03-25
Last Posted Date
2011-10-04
Lead Sponsor
AstraZeneca
Target Recruit Count
98
Registration Number
NCT00642811
Locations
🇬🇧

Research Site, Sheffield, United Kingdom

Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

Phase 2
Completed
Conditions
Diabetes Mellitus
Coronary Artery Disease
Interventions
First Posted Date
2008-03-24
Last Posted Date
2010-02-23
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
35
Registration Number
NCT00642174
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States

Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity

Phase 3
Terminated
Conditions
Stable Angina Pectoris
Ad Hoc Percutaneous Coronary Intervention
Interventions
First Posted Date
2008-03-19
Last Posted Date
2010-03-23
Lead Sponsor
University of Pecs
Target Recruit Count
500
Registration Number
NCT00638326
Locations
🇭🇺

Heart Institute, University of Pécs, Dept. of Interventional Cardiology, Pécs, Hungary

STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction

Phase 3
Completed
Conditions
Myocardial Infarction
Interventions
Drug: enoxaparin
Procedure: primary PCI
Procedure: catheterisation
Drug: tenecteplase
Drug: clopidogrel
First Posted Date
2008-02-26
Last Posted Date
2019-08-01
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1899
Registration Number
NCT00623623
Locations
🇮🇹

1123.28.39001A Boehringer Ingelheim Investigational Site, Monza, Italy

🇫🇷

1123.28.3329A Boehringer Ingelheim Investigational Site, Aubervilliers Cedex, France

🇫🇷

1123.28.3329C Boehringer Ingelheim Investigational Site, Aubervilliers Cedex, France

and more 197 locations

Safety of High-dose Tirofiban During Coronary Angioplasty

Phase 4
Completed
Conditions
Coronary Artery Disease
Interventions
First Posted Date
2007-12-04
Last Posted Date
2011-02-02
Lead Sponsor
S. Anna Hospital
Target Recruit Count
2000
Registration Number
NCT00566891
Locations
🇮🇹

S Anna Hospital, Catanzaro, Italy

© Copyright 2025. All Rights Reserved by MedPath